Surely we haven’t gone from all this hype and communication from the company regarding the exciting potential for Paxalisib to now nothing? Surely this announcement doesn’t warrant the share price to be where it is this morning based on this does it? Management needs to clarify what the future is for KZA and where they see it heading out n the next 12 months. But on the surface not a very pleasing read!!
Ann: GBM Agile Update, page-25
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)